Tapering / Withdrawal
Phenibut Withdrawal Protocol
Science-based GABA-B support protocol from peer-reviewed clinical literature
WARNING
Phenibut withdrawal can be life-threatening. 24-48% of severe cases in clinical literature required mechanical ventilation. Medical supervision is strongly recommended for doses above 1000mg/day. This stack is for harm reduction information only — not a substitute for medical care. In Germany, Phenibut is controlled under the NpSG.
This stack is based on published clinical research and toxicology case studies for managing Phenibut withdrawal. Phenibut acts as a full GABA-B agonist and α2δ VDCC blocker. Abrupt cessation causes dangerous rebound excitotoxicity. The gold standard treatment is Baclofen substitution (10mg Baclofen per 1g Phenibut) with gradual tapering.
Prescription Medications
RxClinical gold standard medications for Phenibut withdrawal management
| Compound | Class | Mechanism | Role in Protocol | Priority |
|---|---|---|---|---|
Baclofen (page coming soon) | Skeletal Muscle Relaxant / Spasmolytic | Selective full GABA-B Agonist | Primary substitute. Used at 10:1 (mg:g) ratio to Phenibut. 10mg Baclofen per 1g Phenibut daily. Administer 3-4x daily for stable plasma levels. Clinical gold standard for severe Phenibut dependence. | Primary |
Gabapentin (page coming soon) | Anticonvulsant / Gabapentinoid | α2δ-subunit VDCC Blocker | Replaces the VDCC-blocking effect lost during Phenibut withdrawal. Addresses gabapentinoid component of dependence. Typical dose 300-900mg TID. | Recommended |
Pregabalin (page coming soon) | Anticonvulsant / Gabapentinoid | α2δ-subunit VDCC Blocker | Higher potency and more predictable pharmacokinetics than Gabapentin. Better oral bioavailability. Preferred over Gabapentin for predictable dosing. | Recommended |
Diazepam / Lorazepam (page coming soon) Risk of cross-dependence. Use only under medical supervision for acute crisis management. | Benzodiazepine | GABA-A Positive Allosteric Modulator (PAM) | Treatment of severe acute withdrawal symptoms. Seizure prophylaxis and sedation. Short-term use only during acute withdrawal crisis. | Caution |
Phenobarbital (page coming soon) ICU setting only. Not for outpatient use. High risk of respiratory depression. | Barbiturate | GABA-A Prolongation & Direct Agonism | Emergency therapy for treatment-refractory withdrawal. Global CNS depression in severe delirium. Intensive care setting only. | Caution |
Clonidine / Dexmedetomidine (page coming soon) | Sympatholytic | α2-adrenergic presynaptic Agonist | Suppresses noradrenaline release. Reduces autonomic hyperactivity: tachycardia, hypertension, sweating, tremors. Adjunct therapy alongside Baclofen. | Recommended |
Buprenorphine / Naloxone (page coming soon) Only relevant in Phenibut + opioid/Kratom polydrug cases. | Partial Opioid Agonist / Antagonist | μ-Opioid Receptor Modulation | Specific use in combined Phenibut and Kratom dependence. Addresses opioid component while Baclofen covers GABA-B component. Case reports document successful dual withdrawal management. | Optional |
OTC & Experimental Compounds
OTC compounds with documented mechanisms for GABA-B upregulation and glutamate modulation
| Compound | Class | Mechanism | Role in Protocol | Priority |
|---|---|---|---|---|
Fasoracetam (page coming soon) DO NOT take concurrently with Phenibut. A clinical case documented life-threatening intoxication (bradycardia, loss of consciousness) when a patient combined 10g Phenibut with Fasoracetam. Use only AFTER stopping Phenibut. | Experimental Nootropic / Racetam | mGluR Activator → forces GABA-B receptor upregulation | Most researched OTC compound for Phenibut recovery. Activates intracellular cascades that upregulate GABA-B receptor density — directly reverses the downregulation caused by chronic Phenibut use. Half-life 4-6.5h, 79-97% oral bioavailability. | Primary |
Agmatine Sulfate (page coming soon) | OTC Supplement / Polyamine | NMDA Antagonist / NOS Inhibitor | Blocks calcium influx, stops excitotoxic glutamate cascades, restores GABA/glutamate balance. Inhibits NMDA receptors at GABA interneurons, increasing extracellular GABA levels. Endogenous metabolite of L-Arginine. | Recommended |
Homotaurine (page coming soon) | OTC (Red Algae Derivative) | GABA-A Agonist / GABA-B Partial Antagonist | Competes at GABA-B receptor without fully activating it. This partial antagonism prevents receptor desensitization and promotes upregulation. Better CNS penetration than taurine due to structural modification. | Optional |
Emoxypine (Mexidol) (page coming soon) | OTC Nootropic / Membrane Stabilizer | Membrane Stabilizer / Antioxidant | Modifies neuronal membrane lipid composition, increases membrane fluidity, induces conformational changes in embedded GABA receptor complexes. Dramatically increases binding affinity of endogenous GABA to existing receptors. Widely available in Russia and some EU countries. | Recommended |
NAC (N-Acetyl Cysteine) (page coming soon) | OTC Supplement / Amino Acid Derivative | Cystine-Glutamate Antiporter Modulator | Stimulates inhibitory presynaptic mGluR2/3 autoreceptors via Cystine-Glutamate Antiporter (System Xc-). Reduces vesicular glutamate release, counteracting the glutamate excess that drives Phenibut withdrawal excitotoxicity. | Recommended |
Memantine (page coming soon) Requires prescription in EU. Off-label use. | Prescription (Off-Label) | Uncompetitive NMDA Channel Blocker | Like Agmatine, prevents excessive calcium influx and protects against neuronal hyperexcitability without total CNS depression. FDA-approved for Alzheimer's. Used off-label in withdrawal syndromes. Requires prescription in EU. | Optional |
Sources
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT